175 related articles for article (PubMed ID: 9219506)
1. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
[TBL] [Abstract][Full Text] [Related]
2. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
4. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
Balachandran R; Welsh MJ; Day BW
Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Banerjee A
Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
[TBL] [Abstract][Full Text] [Related]
7. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
8. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
10. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
[TBL] [Abstract][Full Text] [Related]
11. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
12. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
13. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny MV; Giannakakou P; el-Deiry WS; Kingston DG; Higgs PI; Neckers L; Fojo T
Cancer Res; 1997 Jan; 57(1):130-5. PubMed ID: 8988053
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
Giannakakou P; Sackett DL; Kang YK; Zhan Z; Buters JT; Fojo T; Poruchynsky MS
J Biol Chem; 1997 Jul; 272(27):17118-25. PubMed ID: 9202030
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
[TBL] [Abstract][Full Text] [Related]
16. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
[TBL] [Abstract][Full Text] [Related]
19. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]